ارتباط متقابل اتوفاژی و آپوپتوز در پیشرفت بدخیمی هپاتوسلولار کارسینوما

نوع مقاله : مقاله مروری

نویسندگان

1 دانشجوی دکتری بیولوژی تکوینی، مرکز تحقیقات علوم سلولی، پژوهشکده‌ی سلول‌های بنیادی، پژوهشگاه رویان، تهران، ایران

2 دانشجوی دکتری علوم سلولی کاربردی، دانشکده‌ی فن‌آوری‌های نوین پزشکی، جهاد دانشگاهی پژوهشگاه رویان، تهران، ایران

3 دانشجوی دکتری بیوتکنولوژی پزشکی، مرکز تحقیقات علوم سلولی، پژوهشکده‌ی سلول‌های بنیادی، پژوهشگاه رویان، تهران، ایران

4 استادیار، مرکز تحقیقات علوم سلولی، پژوهشکده‌ی سلول‌های بنیادی، پژوهشگاه رویان، تهران، ایران

5 دانشیار، مرکز تحقیقات علوم سلولی، پژوهشکده‌ی سلول‌های بنیادی، پژوهشگاه رویان، تهران، ایران

چکیده

هپاتوسلولار کارسینوما (Hepatocellular carcinoma یا HCC) شایع‌ترین نوع بدخیمی کبد و بر اساس به‌روزرسانی اخیر Globocan در سال 2020، سومین علت مرگ و میر مرتبط با سرطان در جهان است. یکی از اهداف اصلی روش‌‌های درمانی مرسوم این بدخیمی، القای مرگ برنامه‌ریزی شده (آپوپتوز) در سلول‌های توموری است. از جمله مکانیسم‌های مهم تأثیرگذار در پاسخ سلول‌های توموری به آپوپتوز، فرایند اتوفاژی است. اتوفاژی، یک فرایند تخریب وابسته به لیزوزوم حفاظت شده است که به حفظ هموستاز و سازگاری متابولیکی سلول کمک می‌کند. آپوپتوز و اتوفاژی، دو مکانیسم اصلی در تنظیم مرگ و زنده‌مانی سلولی هستند. افزایش اتوفاژی در مراحل مختلف هپاتوسلولار کارسینوما، با افزایش بقای سلول‌های توموری و پیشرفت بدخیمی مرتبط است و از این طریق، فرار سلول‌های سرطانی از آپوپتوز را تسهیل می‌کند. مطالعات متعددی که به بررسی اثر مهار اتوفاژی در القای آپوپتوز سلول‌های توموری هپاتوسلولار کارسینوما پرداخته‌اند، حاکی از افزایش اثرات درمانی القا کننده‌های آپوپتوز پس از مهار اتوفاژی است. این مطالعه، به بررسی ارتباط متقابل اتوفاژی و آپوپتوز در بقای سلول‌های توموری هپاتوسلولار کارسینوما و تغییرات هدفمند تعادل بین این دو فرایند در درمان این بدخیمی پرداخته است.

کلیدواژه‌ها

عنوان مقاله [English]

Autophagy and Apoptosis Crosstalk in Hepatocellular Carcinoma Progression

نویسندگان [English]

  • Homeyra Seydi 1
  • Shukoofeh Torabi 2
  • Roya Ramezankhani 2
  • Bahareh Shokoohian 3
  • Faezeh Shekari 4
  • Massoud Vosough 5
1 PhD Student in Developmental Biology, Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, The Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
2 PhD Student in Applied Cell Sciences, Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, The Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
3 PhD Student in Medical Biotechnology, Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, The Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
4 Assistant professor, Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, The Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
5 Associate Professor, Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, The Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
چکیده [English]

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the third cause of cancer-related death worldwide based on a recent update of Globocan in 2020. The induction of programmed cell death (apoptosis) in tumor cells is one of the main targets of conventional therapies in cancer. One of the key mechanisms that impacts tumor cells apoptotic response is autophagy. Autophagy is a conserved lysosome-dependent degradation process that aids in the maintenance of cell homeostasis and metabolic compatibility. Apoptosis and autophagy are two main processes in controlling cell death and survival. Enhanced autophagy at various stages of HCC is related to increased tumor cells survival and malignancy development, allowing cancer cells to evade apoptosis. Various studies that investigated the effect of autophagy inhibition on apoptosis induction in HCC cells indicated that apoptosis inducers have a stronger therapeutic impact after autophagy inhibition. In this study, the crosstalk between autophagy and apoptosis in cells survival, as well as targeted alterations in the balance between these processes in HCC therapy are investigated.

کلیدواژه‌ها [English]

  • Liver neoplasms
  • Hepatocellular carcinoma
  • Apoptosis
  • Autophagy

مراجع

  1. Ruoss M, Damm G, Vosough M, Ehret L, Grom-Baumgarten C, Petkov M, et al. Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity. Int J Mol Sci 2019; 20(2): 347
  2. Heydari Z, Najimi M, Mirzaei H, Shpichka A, Ruoss M, Farzaneh Z, et al. Tissue Engineering in Liver Regenerative Medicine: Insights into Novel Translational Technologies. Cells 2020; 9(2): 304.
  3. Vosough M, Moslem M, Pournasr B, Baharvand H. Cell-based therapeutics for liver disorders. Br Med Bull 2011; 100: 157-72.
  4. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol 2020; 72(2): 250-61.
  5. The Global Cancer Observatory. Cancer Tomorrow [Online]. [cited 2021]; Available from: URL: https://gco.iarc.fr/tomorrow/en
  6. Koo SY, Park EJ, Lee CW. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma. Exp Mol Med 2020; 52(8): 1209-19.
  7. Kiruthiga C, Devi KP, Nabavi SM, Bishayee A. Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma. Cancers (Basel) 2020; 12(3): 562.
  8. Shahriari Felordi M, Torabi S, Shokoohian B, Farzaneh Z, Mohamadnejad M, Malekzadeh R, et al. Novel Cell-Based Therapies in Hepatic Disorders. J Mazand Univ Med Sci 2020; 30(185): 184-208. [In Persian].
  9. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology 2021; 73(S1): 4-9.
  10. Mardpour S, Hassani SN, Mardpour S, Sayahpour F, Vosough M, Ai J, et al. Extracellular vesicles derived from human embryonic stem cell-MSCs ameliorate cirrhosis in thioacetamide-induced chronic liver injury. J Cell Physiol 2018; 233(12): 9330-44.
  11. Nahand JS, Jamshidi S, Hamblin MR, Mahjoubin-Tehran M, Vosough M, Jamali M, et al. Circular RNAs: New Epigenetic Signatures in Viral Infections. Front Microbiol 2020; 11: 1853.
  12. Esmaeilzadeh A, Ommati H, Kooshyar MM, Jarahi L, Akhavan RK, Saberi S, et al. Autologous Bone Marrow Stem Cell Transplantation in Liver Cirrhosis after Correcting Nutritional Anomalies, A Controlled Clinical Study. Cell J 2019; 21(3): 268-73.
  13. Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: Looking outside the box. J Hepatol 2020; 72(2): 342-52.
  14. Tompkins KD, Thorburn A. Regulation of apoptosis by autophagy to enhance cancer therapy. Yale J Biol Med 2019; 92(4): 707-18.
  15. Farzaneh Z, Vosough M, Agarwal T, Farzaneh M. Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches. Cancer Cell Int 2021; 21(1): 208.
  16. Liu B, Oltvai ZN, Bayir H, Silverman GA, Pak SC, Perlmutter DH, et al. Quantitative assessment of cell fate decision between autophagy and apoptosis. Sci Rep 2017; 7(1): 17605.
  17. Lee YJ, Jang BK. The Role of Autophagy in Hepatocellular Carcinoma. Int J Mol Sci 2015; 16(11): 26629-43.
  18. Shafabakhsh R, Arianfar F, Vosough M, Mirzaei HR, Mahjoubin-Tehran M, Khanbabaei H, et al. Autophagy and gastrointestinal cancers: the behind the scenes role of long non-coding RNAs in initiation, progression, and treatment resistance. Cancer Gene Ther 2021.
  19. Fairlie WD, Tran S, Lee EF. Crosstalk between apoptosis and autophagy signaling pathways. Int Rev Cell Mol Biol 2020; 352: 115-58.
  20. Lomonosova E, Chinnadurai G. BH3-only proteins in apoptosis and beyond: An overview. Oncogene 2008; 27(Suppl 1): S2-19.
  21. Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ 2018; 25(1): 104-13.
  22. Pang L, Liu K. Tumor-suppressing effects of autophagy on hepatocellular carcinoma. Liver Research 2018; 2(3): 157-60.
  23. Liu L, Liao JZ, He XX, Li PY. The role of autophagy in hepatocellular carcinoma: friend or foe. Oncotarget 2017; 8(34): 57707-22.
  24. Towers CG, Wodetzki D, Thorburn A. Autophagy and cancer: Modulation of cell death pathways and cancer cell adaptations. J Cell Biol 2020; 219(1).
  25. Pourhanifeh MH, Vosough M, Mahjoubin-Tehran M, Hashemipour M, Nejati M, Abbasi-Kolli M, et al. Autophagy-related microRNAs: Possible regulatory roles and therapeutic potential in and gastrointestinal cancers. Pharmacol Res 2020; 161: 105133.
  26. Xue F, Hu L, Ge R, Yang L, Liu K, Li Y, et al. Autophagy-deficiency in hepatic progenitor cells leads to the defects of stemness and enhances susceptibility to neoplastic transformation. Cancer Lett 2016; 371(1): 38-47.
  27. Gao L, Loveless J, Shay C, Teng Y. Targeting ROS-Mediated Crosstalk Between Autophagy and Apoptosis in Cancer. Adv Exp Med Biol 2020; 1260: 1-12.
  28. Zhao GX, Pan H, Ouyang DY, He XH. The critical molecular interconnections in regulating apoptosis and autophagy. Ann Med 2015; 47(4): 305-15.
  29. Thorburn A. Apoptosis and autophagy: regulatory connections between two supposedly different processes. Apoptosis 2008; 13(1): 1-9.
  30. Noguchi M, Hirata N, Edamura T, Ishigaki S, Suizu F. Intersection of apoptosis and autophagy cell death pathways. Austin J Mol Cell Biol 2015; 2(1): 1004.
  31. El-Khattouti A, Selimovic D, Haikel Y, Hassan M. Crosstalk between apoptosis and autophagy: molecular mechanisms and therapeutic strategies in cancer. J Cell Death 2013; 6: 37-55.
  32. Wu DH, Jia CC, Chen J, Lin ZX, Ruan DY, Li X, et al. Autophagic LC3B overexpression correlates with malignant progression and predicts a poor prognosis in hepatocellular carcinoma. Tumour Biol 2014; 35(12): 12225-33.
  33. Tian Y, Kuo CF, Sir D, Wang L, Govindarajan S, Petrovic LM, et al. Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis. Cell Death Differ 2015; 22(6): 1025-34.
  34. Yang J, Pi C, Wang G. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother 2018; 103: 699-707.
  35. Wu R, Murali R, Kabe Y, French SW, Chiang YM, Liu S, et al. Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition. Hepatology 2018; 68(5): 1726-40.
  36. Chen L, Ye HL, Zhang G, Yao WM, Chen XZ, Zhang FC, et al. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells. PLoS One 2014; 9(1): e85771.
  37. Yuan H, Li AJ, Ma SL, Cui LJ, Wu B, Yin L, et al. Inhibition of autophagy signi fi cantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells. World J Gastroenterol 2014; 20(17): 4953-62.
  38. Gavini J, Dommann N, Jakob MO, Keogh A, Bouchez LC, Karkampouna S, et al. Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. Cell Death Dis 2019; 10(10): 749.
  39. Lee YG, Jeon TI. Modulation of the Autophagy-lysosomal Pathway in Hepatocellular Carcinoma Using Small Molecules. Molecules 2020; 25(7).
  40. Pan H, Wang Z, Jiang L, Sui X, You L, Shou J, et al. Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib. Sci Rep 2014; 4: 6683.
  41. Du H, Yang W, Chen L, Shi M, Seewoo V, Wang J, et al. Role of autophagy in resistance to oxaliplatin in hepatocellular carcinoma cells. Oncol Rep 2012; 27(1): 143-50.
  42. Li Q, Ni Y, Zhang L, Jiang R, Xu J, Yang H, et al. HIF-1alpha-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation. Signal Transduct Target Ther 2021; 6(1): 76.
  43. Shi YM, Yang L, Geng YD, Zhang C, Kong LY. Polyphyllin I induced-apoptosis is enhanced by inhibition of autophagy in human hepatocellular carcinoma cells. Phytomedicine 2015; 22(13): 1139-49.
  44. Luo L, Sun W, Zhu W, Li S, Zhang W, Xu X, et al. BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism. Cell Death Dis 2021; 12(2): 169.
  45. Okubo S, Ohta T, Fujita H, Shoyama Y, Uto T. Costunolide and dehydrocostuslactone from Saussurea lappa root inhibit autophagy in hepatocellular carcinoma cells. J Nat Med 2021; 75(1): 240-5.
  46. Zhu C, Zhao M, Fan L, Cao X, Xia Q, Zhou J, et al. Chitopentaose inhibits hepatocellular carcinoma by inducing mitochondrial mediated apoptosis and suppressing protective autophagy. Bioresources and Bioprocessing 2021; 8(1): 4.
  47. Ashrafizadeh M, Zarrabi A, Hashemipour M, Vosough M, Najafi M, Shahinozzaman M, et al. Sensing the scent of death: Modulation of microRNAs by Curcumin in gastrointestinal cancers. Pharmacological Research 2020; 160: 105199.
  48. Pomatto MAC, Bussolati B, D'Antico S, Ghiotto S, Tetta C, Brizzi MF, et al. Improved Loading of Plasma-Derived Extracellular Vesicles to Encapsulate Antitumor miRNAs. Mol Ther Methods Clin Dev 2019; 13: 133-44.
  49. Fu XT, Shi YH, Zhou J, Peng YF, Liu WR, Shi GM, et al. MicroRNA-30a suppresses autophagy-mediated anoikis resistance and metastasis in hepatocellular carcinoma. Cancer Lett 2018; 412: 108-17.
  50. Jin F, Wang Y, Li M, Zhu Y, Liang H, Wang C, et al. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis 2017; 8(1): e2540.
  51. Zhang K, Chen J, Zhou H, Chen Y, Zhi Y, Zhang B, et al. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib. Cell Death Dis 2018; 9(3): 312.
  52. Zhou Y, Chen E, Tang Y, Mao J, Shen J, Zheng X, et al. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells. Cell Death Dis 2019; 10(11): 843.
  53. Shi Y, Yang X, Xue X, Sun D, Cai P, Song Q, et al. HANR Enhances Autophagy-Associated Sorafenib Resistance Through miR-29b/ATG9A Axis in Hepatocellular Carcinoma. Onco Targets Ther 2020; 13: 2127-37.
  54. Chang Y, Yan W, He X, Zhang L, Li C, Huang H, et al. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology 2012; 143(1): 177-87.
  55. Yang S, Wang M, Yang L, Li Y, Ma Y, Peng X, et al. MicroRNA-375 Targets ATG14 to Inhibit Autophagy and Sensitize Hepatocellular Carcinoma Cells to Sorafenib. Onco Targets Ther 2020; 13: 3557-70.

فایل ها

سابقه مقاله

  • تاریخ دریافت: 23 اسفند 1399
  • تاریخ بازنگری: 11 آبان 1403
  • تاریخ پذیرش: 17 فروردین 1401

هم رسانی

ارجاع به این مقاله

آمار